In this sub-therapeutic CAR-T model, we observed a slight decrease in relative bioluminescence-measured tumor burden of mice receiving Thor + [225Ac]Ac-Pr versus Thor-cells alone, or those receiving 19BBz ± [225Ac]Ac-Pr (Figure S17B). The gene discussed is THORLNC; the disease is neoplasm.